The value of positron emission tomography in early detection of lung cancer in high-risk population: A systematic review

Clinical Respiratory Journal

Volumn 7, Issue 1, 2013, Pages 1-6

  Chang, Cheng Yu ^a   Chang, Shu Ju ^b   Chang, Shih Chieh ^c   Yuan, Mei Kang ^c  

^a FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

^b ALETHEIA UNIVERSITY   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Early lung cancer; Positron emission tomography; Screening

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

BRONCHOALVEOLAR CELL CARCINOMA; CANCER DIAGNOSIS; CARCINOID; HIGH RISK POPULATION; HUMAN; LOW DOSE SPIRAL CHEST COMPUTED TOMOGRAPHY; LUNG ADENOCARCINOMA; LUNG CANCER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW;

EARLY DIAGNOSIS; HUMANS; LUNG NEOPLASMS; MASS SCREENING; POSITRON-EMISSION TOMOGRAPHY; RISK FACTORS;

EID: 84875645629     PISSN: 17526981     EISSN: 1752699X     Source Type: Journal    
DOI: 10.1111/j.1752-699X.2012.00290.x     Document Type: Review

References (15)

1. Patz EF Jr, Goodman PC, Bepler G. Screening for lung cancer. N Engl J Med. 2000;343: 1627-33.
2. Kendal WS. Chance mechanisms affecting the burden of metastases. BMC Cancer. 2005;5: 138.
3. Swensen S, Aberle CD, Kazerooni EA, etal. Consensus statement: CT screening for lung cancer. J Thorac Imaging. 2005;20: 321.
4. Moher D, Liberati A, Tetzlaff J, Altman DG. The PRISMA Group (2008) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement. PLoS Med. 2009;6: e1000097.
5. Pastorino U, Bellomi M, Landoni C, etal. Early lung-cancer detection with spiral CT and positron emission tomography in heavy smokers: 2-year results. Lancet. 2003;362: 593-7.
6. Lindell RM, Hartman TE, Swensen SJ, etal. Lung cancer screening experience: a retrospective review of PET in 22 non-small cell lung carcinomas detected on screening chest CT in a high-risk population. Am J Roentgenol. 2005;185: 126-31.
7. Marom EM, Sarvis S, Herndon JE II, Patz EF Jr. T1 lung cancers: sensitivity of diagnosis with fluorodeoxyglucose PET. Radiology. 2002;223: 453-9.
8. Pastorino U, Landoni C, Marchianò A, etal. Fluorodeoxyglucose uptake measured by positron emission tomography and standardized uptake value predicts long-term survival of CT screening detected lung cancer in heavy smokers. J Thorac Oncol. 2009;4: 1352-6.
9. Kagna O, Solomonov A, Keidar Z, etal. The value of FDG-PET/CT in assessing single pulmonary nodules in patients at high risk of lung cancer. Eur J Nucl Med Mol Imaging. 2009;36: 997-1004.
10. Schöder H, Gönen M. Screening for cancer with PET and PET/CT: Potential and Limitations. J Nucl Med. 2007;48(Suppl. 1): 4S-18S.
11. Gomez M, Silvestri GA. Lung cancer screening. Am J Med Sci. 2008;335: 46-50.
12. Ashraf H, Dirksen A, Loft A, etal. Combined use of positron emission tomography and volume doubling time in lung cancer screening with low-dose CT scanning. Thorax. 2011;66: 315-19.
13. ICRP. Radiation dose to patients from radiopharmaceuticals. Addendum 3 to ICRP Publication 53. ICRP Publication 106. Approved by the Commission in October 2007. Ann ICRP. 2008;38: 1-197.
14. Boellaard R, O'Doherty MJ, Weber WA, etal. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2010;37: 181-200.
15. Weng MJ, Wu MT, Pan HB, etal. The feasibility of low-dose CT for pulmonary metastasis in patients with primary gynecologic malignancy. Clin Imaging. 2004;28: 408-14.